The study results showed significant decrease in VAS scores over 14 days of treatment
A recently published study in the International Journal of Nutrition and Food Sciences has shown positive results for the effects of Gencor’s Levagen+ ingredient on joint discomfort. The study assessed the efficacy of the company’s dispersible Palmitoylethanolamide – PEA (Levagen+) in alleviating joint discomfort and improving quality of life in adults.
The product uses LipiSperse, Pharmako Biotechnologies’ cold water dispersion technology, and has reportedly been shown to increase the absorption of in comparison to standard PEA. The randomised, double-blind study compared the efficacy of a 350 mg dose of Levagen+ PEA to placebo on relieving joint discomfort in healthy adults aged between 25 and 70 years. Participants in the PEA group consumed 175 mg of Levagen+ twice daily with water throughout a two-week period.
“We are thrilled with the results of this study that further validates the potent effects of Levagen+ and suggests that PEA may be a safe and beneficial treatment for individuals with joint health related concerns,” said Chase Shryoc, VP of Sales & Business Development for Gencor. “With its anti-inflammatory and analgesic proprieties, along with its ability to influence the endocannabinoid system, Levagen+ PEA can play a critical role in supporting joint function.”
During the study, both groups demonstrated an early reduction in VAS (visual analog scale) pain scores compared to baseline values until approximately day 10, at which point the scores plateaued and increased in the placebo group while continuing to decrease in the PEA group. The study also used a lower dose of Levagen+ compared to 600 mg dose of standard PEA that has been used in previous trials to study PEA’s benefits for joint health.
Levagen+’s dispersion technology means the product can be formulated into effervescent tablets, RTD shots, functional foods, functional beverages, and gummies.